Efficacy and safety of adoptive immunotherapy using anti-CD19 chimeric antigen receptor transduced T-cells: a systematic review of phase I clinical trials

References

• Drake CG, Jaffee E, Pardoll DM. Mechanisms of immune evasion by tumors. Adv Immunol 2006;90:51–81.
   PubMed Web of Science ®Google Scholar
• Ramos CA, Dotti G. Chimeric antigen receptor (CAR)-engineered lymphocytes for cancer therapy. Expert Opin Biol Ther 2011;11: 855–873.
   PubMed Web of Science ®Google Scholar
• Jensen MC, Popplewell L, Cooper LJ, . Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans. Biol Blood Marrow Transplant 2010;16:1245–1256.
   PubMed Web of Science ®Google Scholar
• Pule MA, Savoldo B, Myers GD, . Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med 2008;14:1264–1270.
   PubMed Web of Science ®Google Scholar
• Savoldo B, Ramos CA, Liu E, . CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J Clin Invest 2011;121:1822–1826.
   PubMed Web of Science ®Google Scholar
• Kalos M, Levine BL, Porter DL, . T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 2011;3:95ra73.
   Web of Science ®Google Scholar
• Till BG, Jensen MC, Wang J, . CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results. Blood 2012;119:3940–3950.
   PubMed Web of Science ®Google Scholar
• Hoyos V, Savoldo B, Quintarelli C, . Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety. Leukemia 2010;24:1160–1170.
   PubMed Web of Science ®Google Scholar
• Singh H, Figliola MJ, Dawson MJ, . Reprogramming CD19-specific T cells with IL-21 signaling can improve adoptive immunotherapy of B-lineage malignancies. Cancer Res 2011;71:3516–3527.
   PubMed Web of Science ®Google Scholar
• Pegram HJ, Lee JC, Hayman EG, . Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. Blood 2012;119:4133–4141.
   PubMed Web of Science ®Google Scholar
• Berger C, Jensen MC, Lansdorp PM, . Adoptive transfer of effector CD8 T cells derived from central memory cells establishes persistent T cell memory in primates. J Clin Invest 2008;118:294–305.
   PubMed Web of Science ®Google Scholar
• James SE, Greenberg PD, Jensen MC, . Antigen sensitivity of CD22-specific chimeric TCR is modulated by target epitope distance from the cell membrane. J Immunol 2008;180:7028–7038.
   PubMed Web of Science ®Google Scholar
• Giordano Attianese GM, Marin V, Hoyos V, . In vitro and in vivo model of a novel immunotherapy approach for chronic lymphocytic leukemia by anti-CD23 chimeric antigen receptor. Blood 2011;117:4736–4745.
   PubMed Web of Science ®Google Scholar
• Jena B, Dotti G, Cooper LJ. Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor. Blood 2010;116:1035–1044.
   PubMed Web of Science ®Google Scholar
• Brentjens RJ, Latouche JB, Santos E, . Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nat Med 2003;9:279–286.
   PubMed Web of Science ®Google Scholar
• Barrett DM, Zhao Y, Liu X, . Treatment of advanced leukemia in mice with mRNA engineered T cells. Hum Gene Ther 2011;22:1575–1586.
   PubMed Web of Science ®Google Scholar
• Song DG, Ye Q, Carpenito C, . In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB). Cancer Res 2011;71:4617–4627.
   PubMed Web of Science ®Google Scholar
• Kohn DB, Dotti G, Brentjens R, . CARs on track in the clinic. Mol Ther 2011;19:432–438.
   Google Scholar
• Ertl HC, Zaia J, Rosenberg SA, . Considerations for the clinical application of chimeric antigen receptor T cells: observations from a recombinant DNA Advisory Committee Symposium held June 15, 2010. Cancer Res 2011;71:3175–3181.
   PubMed Web of Science ®Google Scholar
• Kochenderfer JN, Dudley ME, Feldman SA, . B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 2012;119:2709–2720.
   PubMed Web of Science ®Google Scholar
• Kochenderfer JN, Wilson WH, Janik JE, . Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood 2010;116:4099–4102.
   PubMed Web of Science ®Google Scholar
• Brentjens RJ, Riviere I, Park JH, . Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood 2011;118:4817–4828.
   PubMed Web of Science ®Google Scholar
• Porter DL, Levine BL, Kalos M, . Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 2011;365:725–733.
   PubMed Web of Science ®Google Scholar
• Brentjens R, Yeh R, Bernal Y, . Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial. Mol Ther 2010;18:666–668.
   PubMed Web of Science ®Google Scholar
• Burger JA, O’Brien S, Fowler N, . The Bruton's tyrosine kinase inhibitor, PCI-32765, is well tolerated and demonstrates promising clinical activity in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL): an update on ongoing phase 1 studies. Blood 2010;116(Suppl. 1): Abstract 57.
   Google Scholar
• Fowler N, Sharman JP, Smith SM, . The Btk inhibitor, PCI-32765, induces durable responses with minimal toxicity in patients with relapsed/refractory B-cell malignancies: results from a phase I study. Blood 2010;116(Suppl. 1): Abstract 964.
   PubMed Web of Science ®Google Scholar
• Wang LH, Martin P, Blum KA, . The Bruton's tyrosine kinase inhibitor PCI-32765 is highly active as single-agent therapy in previously-treated mantle cell lymphoma (MCL): preliminary results of a phase II trial. Blood 2011;118:203–204.
   Web of Science ®Google Scholar
• Furman RR, Byrd JC, Brown JR, . CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110 delta, demonstrates clinical activity and pharmacodynamic effects in patients with relapsed or refractory chronic lymphocytic leukemia. Blood 2010;116(Suppl. 1): Abstract 55.
   Google Scholar
• Kahl B, Byrd JC, Flinn IW, . Clinical safety and activity in a phase 1 study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110 delta, in patients with relapsed or refractory non-Hodgkin lymphoma. Blood 2010;116(Suppl. 1): Abstract 1777.
   PubMed Web of Science ®Google Scholar
• Roberts AW, Seymour JF, Brown JR, . Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. J Clin Oncol 2012;30:488–496.
   PubMed Web of Science ®Google Scholar
• Doti CA, Bullorsky EO. Hematopoietic stem cell transplantation in the era of tyrosine kinase inhibitors. Leuk Lymphoma 2009;50(Suppl. 2):27–31.
   PubMedGoogle Scholar
• Cui Y, Zhang H, Meadors J, . Harnessing the physiology of lymphopenia to support adoptive immunotherapy in lymphoreplete hosts. Blood 2009;114:3831–3840.
   PubMed Web of Science ®Google Scholar
• Wrzesinski C, Paulos CM, Kaiser A, . Increased intensity lymphodepletion enhances tumor treatment efficacy of adoptively transferred tumor-specific T cells. J Immunother 2010;33:1–7.
   PubMed Web of Science ®Google Scholar
• Caserta S, Alessi P, Basso V, . IL-7 is superior to IL-2 for ex vivo expansion of tumour-specific CD4( ) T cells. Eur J Immunol 2010;40:470–479.
   PubMed Web of Science ®Google Scholar
• Pegram HJ, Lee JC, Hayman EG, . Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. Blood 2012;119:4133–4141.
   PubMed Web of Science ®Google Scholar
• Louis CU, Savoldo B, Dotti G, . Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood 2011;118:6050–6056.
   PubMed Web of Science ®Google Scholar
• Li Z, Dullmann J, Schiedlmeier B, . Murine leukemia induced by retroviral gene marking. Science 2002;296:497.
   PubMed Web of Science ®Google Scholar
• Hacein-Bey-Abina S, von Kalle C, Schmidt M, . A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 2003;348:255–256.
   PubMed Web of Science ®Google Scholar
• Hacein-Bey-Abina S, Von Kalle C, Schmidt M, . LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 2003;302:415–419.
   PubMed Web of Science ®Google Scholar
• Newrzela S, Cornils K, Li Z, . Resistance of mature T cells to oncogene transformation. Blood 2008;112:2278–2286.
   PubMed Web of Science ®Google Scholar
• Recchia A, Bonini C, Magnani Z, . Retroviral vector integration deregulates gene expression but has no consequence on the biology and function of transplanted T cells. Proc Natl Acad Sci USA 2006;103:1457–1462.
   PubMed Web of Science ®Google Scholar
• Walker RE, Bechtel CM, Natarajan V, . Long-term in vivo survival of receptor-modified syngeneic T cells in patients with human immunodeficiency virus infection. Blood 2000;96:467–474.
   PubMed Web of Science ®Google Scholar
• Mitsuyasu RT, Anton PA, Deeks SG, . Prolonged survival and tissue trafficking following adoptive transfer of CD4zeta gene-modified autologous CD4( ) and CD8( ) T cells in human immunodeficiency virus-infected subjects. Blood 2000;96:785–793.
   PubMed Web of Science ®Google Scholar
• Khaleghi S, Rahbarizadeh F, Ahmadvand D, . A caspase 8-based suicide switch induces apoptosis in nanobody-directed chimeric receptor expressing T cells. Int J Hematol 2012;95:434–444.
   PubMed Web of Science ®Google Scholar
• Tey SK, Dotti G, Rooney CM, . Inducible caspase 9 suicide gene to improve the safety of allodepleted T cells after haploidentical stem cell transplantation. Biol Blood Marrow Transplant 2007;13: 913–924.
   PubMed Web of Science ®Google Scholar